AI Article Synopsis
- The study aimed to assess atorvastatin's effectiveness in maintaining stable sinus rhythm (SR) after electrical cardioversion (CV) in patients with chronic atrial fibrillation (AF).
- A total of 234 patients were randomly assigned to receive either atorvastatin or a placebo, with treatment starting 14 days before and continuing 30 days after CV.
- Results showed no significant difference between the atorvastatin and placebo groups in achieving SR 30 days post-CV, indicating that atorvastatin is not more effective than placebo for this purpose.
Article Abstract
Aims: To evaluate the effect of atorvastatin in achieving stable sinus rhythm (SR) 30 days after electrical cardioversion (CV) in patients with persistent atrial fibrillation (AF).
Methods And Results: The study included 234 patients. The patients were randomized to treatment with atorvastatin 80 mg daily (n = 118) or placebo (n = 116) in a prospective, double-blinded fashion. Treatment was initiated 14 days before CV and was continued 30 days after CV. The two groups were well-balanced with respect to baseline characteristics. Mean age was 65 +/- 10 years, 76% of the patients were male and 4% had ischaemic heart disease. Study medication was well-tolerated in all patients but one. Before primary endpoint 12 patients were excluded. In the atorvastatin group 99 patients (89%) converted to SR at electrical CV compared with 95 (86%) in the placebo group (P = 0.42). An intention-to-treat analysis with the available data, by randomization group, showed that 57 (51%) in the atorvastatin group and 47 (42%) in the placebo group were in SR 30 days after CV (OR 1.44, 95%CI 0.85-2.44, P = 0.18).
Conclusion: Atorvastatin was not statistically superior to placebo with regards to maintaining SR 30 days after CV in patients with persistent AF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/eurheartj/ehp006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcatheter Approaches to Atrial Functional Mitral Regurgitation: How Far Have We Come?
Catheter Cardiovasc Interv
December 2024
Heart Valve Center, San Raffaele Hospital, Milan, Italy.
Functional mitral regurgitation (MR) is associated with increased cardiovascular morbidity and mortality and over the past decade, the diagnosis of atrial functional mitral regurgitation (aFMR) has been increasingly observed in the elderly, especially in those with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF). Annular enlargement, perturbations of annular contraction, and atriogenic leaflet tethering distinguish the pathophysiology of aFMR from the one of ventricular origin. However, no consensus provides recommendations regarding the differential diagnosis and the subsequent management of aFMR.
View Article and Find Full Text PDFFetal-to-Neonatal Transition of an Infant with Transposition of the Great Arteries and Intact Ventricular Septum: A Case Report.
Biomed Hub
December 2024
Division of Paediatric Cardiology, Department of Paediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Centre (LUMC), Leiden, The Netherlands.
Introduction: Transposition of the great arteries (TGA), especially with intact ventricular septum (TGA-IVS), presents unique challenges during fetal-to-neonatal transition, which can contribute to developing persistent pulmonary hypertension of the newborn (PPHN).
Case Presentation: A male newborn with TGA-IVS, delivered via caesarean section, presented with hypoxemia and tachycardia immediately after birth (preductal SpO: 50-60%, post-ductal SpO: 70-75%). Echocardiography revealed a floppy interatrial septum and two interatrial connections with bidirectional shunting.
Real-world outcomes in cardiac resynchronization therapy patients: Primary results of the SMART registry.
ESC Heart Fail
December 2024
Boston Scientific Corporation, St. Paul, Minnesota, USA.
Article Synopsis
- Cardiac resynchronization therapy (CRT) is effective for treating heart failure but is under-researched in patients with common comorbidities like atrial fibrillation (AF).
- The SMART registry enrolled 2035 patients to assess CRT response based on clinical outcomes over 12 months, focusing on factors like all-cause mortality, hospitalizations, and quality of life.
- Results showed 58.9% of patients improved, but factors like age, AF, and diabetes were linked to lower CRT responsiveness, with patients having AF experiencing higher rates of hospitalizations and mortality compared to those in normal rhythm.
Ischemic Stroke Prevention in Patients Atrial Fibrillation and a Recent Ischemic Stroke, TIA, or Intracranial Hemorrhage; a World Stroke Organisation (WSO) Scientific Statement.
Int J Stroke
December 2024
Division of Neurology, McMaster University, Hamilton, ON, Canada.
Background: Secondary stroke prevention in patients with atrial fibrillation (AF) is one of the fastest growing areas in the field of cerebrovascular diseases. This Scientific statement from the World Stroke Organization Brain & Heart Task Force provides a critical analysis of the strength of current evidence this topic, highlights areas of current controversy, identifies knowledge gaps, and proposes priorities for future research.
Methods: We select topics with the highest clinical relevance and perform a systematic search to answer specific practical questions.
An uncommon cardiovascular abnormality: Case report of core triatriatum associated with persistent left superior vena cava and coronary sinus dilation.
Radiol Case Rep
February 2025
Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Cor triatriatum is an uncommon cardiac defect that occurs in 0.1-0.4% of congenital heart disease patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!